Science Saturday: Vaccine efforts move forward at Mayo Clinic
Humanity has taken on infectious agents, such as the virus that causes smallpox, and won. But cheer quietly. Smallpox eradication took 200 years, and it's just one of the many diseases out there. But hey, researchers are nothing if not persistent, right? A Mayo Clinic lab member is purifying an adenovirus vector for preclinical testing. That's [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 27, 2021 Category: Databases & Libraries Source Type: news

AstraZeneca ’s U.S. Study May Answer Some of the Lingering Questions About Its Vaccine
This study puts to bed any doubts that this isn’t a highly effective vaccine against COVID-19 disease and COVID-19 symptoms,” says Mene Pangalos, executive vice president for biopharmaceuticals research and development at AstraZeneca. AstraZeneca’s vaccine is based on technology developed by scientists at Oxford University’s Jenner Institute, and involves using a chimpanzee adenovirus modified so it cannot cause the cold infection it normally does. The chimp virus acts as a vehicle to deliver genes into the body, where it encodes the SARS-CoV-2 spike protein; cells then process the protein so the im...
Source: TIME: Health - March 22, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Your coronavirus vaccine guide: Covishield vs Covaxin
Oxford-AstraZeneca made Covishield is based on the viral vector platform. The vaccine is made by genetically engineering adenovirus that normally infects chimpanzees. It uses double-stranded DNA. Bharat Biotech made Covaxin is based on an inactivated form of the coronavirus. (Source: The Economic Times)
Source: The Economic Times - March 2, 2021 Category: Consumer Health News Source Type: news

Study: Which Mesothelioma Patients Will Immunotherapy Benefit?
This study also is designed to better understand the biological mechanisms affecting the immune system. The goal is to use both the cellular organization and molecular pathways to develop a test that can predict the response to the checkpoint inhibitor drugs. Upon completion, a clinical trial would follow, in which treatment would depend on the results of the individual’s test. “Within the next year or two, we’ll have a good idea of whether these components are working,” Burt said. The post Study: Which Mesothelioma Patients Will Immunotherapy Benefit? appeared first on Mesothelioma Center - Vital S...
Source: Asbestos and Mesothelioma News - February 23, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news

FDA Fast-Tracks Mesothelioma Vaccine Development
The U.S. Food and Drug Administration has granted Fast-Track Designation this week to ONCOS-102, an immunotherapy vaccine that targets malignant mesothelioma and other hard-to-treat tumors. This designation is expected to expedite the regulatory approval process. The vaccine’s developer, Targovax, a small biotech company that focuses on oncolytic viruses, sees this as an early endorsement from the FDA. “Yes, this opens the door for us,” Dr. Magnus Jaderberg, chief medical officer of Targovax, told The Mesothelioma Center at Asbestos.com. “It validates what the FDA believes is a potentially promising...
Source: Asbestos and Mesothelioma News - February 19, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news

Optimizing Adeno-Associated Virus (AAV) Manufacturing
Scientists wield nature ’s power to optimize adeno-associated virus (AAV) production and maximize gene therapy safety. (Source: The Scientist)
Source: The Scientist - February 16, 2021 Category: Science Tags: Research Products Blog Source Type: news

Zika vaccine candidate shows promise in phase I trial
(American College of Physicians) The Zika virus candidate, Ad26.ZIKV.001, a replication-incompetent human adenovirus serotype 26 (ad26) vector showed promising safety and immunogenicity in a phase I clinical trial. Researchers say the vaccine warrants further development should the need reemerge. The findings are published in Annals of Internal Medicine. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 15, 2021 Category: Infectious Diseases Source Type: news

A new vision for adeno-associated virus delivered gene therapies
An international collaboration of leading groups in gene therapy and vision science have developed an adeno-associated virus (AAV) genome-coupled immunomodulation strategy that helps cloak the AAV virus from unwanted immune responses and offers important insights into ocular inflammation. The research led by Harvard University, Harvard Medical School and including the University of Bristol is published in Science Translational Medicine. (Source: University of Bristol news)
Source: University of Bristol news - February 11, 2021 Category: Universities & Medical Training Tags: Health, International, Research; Faculty of Health Sciences, Faculty of Health Sciences, Translational Health Sciences, Faculty of Life Sciences, Faculty of Life Sciences, School of Cellular and Molecular Medicine; Press Release Source Type: news

Do Vaccines Stop the Spread of COVID-19? What You Need to Know
The way most people think of vaccines is pretty simple: you get vaccinated, and your immune system is primed and trained to fight off the invisible intruder in question, be it virus or bacteria. If you’re protected, you can’t be infected, and if you’re not infected, then you can’t spread it to anyone else. And that’s true most of the time. But not all vaccines work that way, and it’s not actually what the two COVID-19 vaccines authorized by the U.S. Food and Drug Administration—made by Moderna and Pfizer-BioNtech—are designed to do. Their effectiveness is measured by how well...
Source: TIME: Health - February 11, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

High Efficacy Reported for Sputnik V COVID-19 Vaccine
THURSDAY, Feb. 4, 2021 -- A heterologous recombinant adenovirus (rAd)-based vaccine, Gam-COVID-Vac (Sputnik V), has 91.6 percent efficacy against COVID-19, according to a study published online Feb. 2 in The Lancet. Denis Y. Logunov, D.Sc., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 4, 2021 Category: Pharmaceuticals Source Type: news

Intranasal influenza vaccine spurs strong immune response in Phase 1 study
(NIH/National Institute of Allergy and Infectious Diseases) An experimental single-dose, intranasal influenza vaccine was safe and produced a durable immune response when tested in a Phase 1 study published in theJournal of Clinical Investigation. The investigational vaccine, called Ad4-H5-VTN, is a recombinant, replicating adenovirus vaccine designed to spur antibodies to hemagglutinin, a protein found on the surface of influenza viruses that attaches to human cells. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 3, 2021 Category: Infectious Diseases Source Type: news

Lancet peer-reviewed study endorses Russia's Sputnik V Covid-19 vaccine
Sputnik V uses two adenoviruses, AD 5 and AD 26, that target the spike protein of the SARS Cov2 virus. Companies such as AstraZeneca, Johnson& Johnson and CanSino are using one of these 2 vectors for their vaccines. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 3, 2021 Category: Pharmaceuticals Source Type: news

The Lancet: Study reports preliminary efficacy and safety results from interim analysis of Russian COVID-19 phase 3 vaccine trial
(The Lancet) An interim analysis of data from the phase 3 trial of the COVID-19 vaccine from Russia (Gam-COVID-Vac) suggests that a two-dose regimen of the adenovirus-based vaccine offers 91.6% efficacy against symptomatic COVID-19. The preliminary findings, published in The Lancet, are based on analysis of data from nearly 20,000 participants, three-quarters of whom received the vaccine and one quarter received a placebo. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 2, 2021 Category: Infectious Diseases Source Type: news

AAVCOVID single-dose, room temperature-stable COVID-19 vaccine supported by new funding
(Massachusetts Eye and Ear Infirmary) The AAVCOVID vaccine program, a novel gene-based vaccine strategy that utilizes an adeno-associated virus (AAV) vector, was granted an award for up to $2.1 million from the Bill& Melinda Gates Foundation. The grant will aid the effort to bring further preclinical validation to the AAVCOVID platform and its single-dose, room temperature stable vaccine candidates. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - January 29, 2021 Category: Infectious Diseases Source Type: news

MAIT cell activation augments adenovirus vector vaccine immunogenicity
Mucosal-associated invariant T (MAIT) cells are innate sensors of viruses and can augment early immune responses and contribute to protection. We hypothesized that MAIT cells may have inherent adjuvant activity in vaccine platforms that use replication-incompetent adenovirus vectors. In mice and humans, ChAdOx1 (chimpanzee adenovirus Ox1) immunization robustly activated MAIT cells. Activation required plasmacytoid dendritic cell (pDC)–derived interferon (IFN)–α and monocyte-derived interleukin-18. IFN-α–induced, monocyte-derived tumor necrosis factor was also identified as a key secondary sign...
Source: ScienceNOW - January 28, 2021 Category: Science Authors: Provine, N. M., Amini, A., Garner, L. C., Spencer, A. J., Dold, C., Hutchings, C., Silva Reyes, L., FitzPatrick, M. E. B., Chinnakannan, S., Oguti, B., Raymond, M., Ulaszewska, M., Troise, F., Sharpe, H., Morgan, S. B., Hinks, T. S. C., Lambe, T., Capone, Tags: Immunology, Microbiology reports Source Type: news

Biodistribution of AAV gene transfer vectors in nonhuman primate
(Mary Ann Liebert, Inc./Genetic Engineering News) The biodistribution of adeno-associated virus (AAV) gene transfer vectors can be measured in nonhuman primates using a new method. The method quantifies whole-body and organ-specific AAV capsids from 1 to 72 hours after administration (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 15, 2021 Category: International Medicine & Public Health Source Type: news

Johnson & Johnson ’s 1-Shot COVID-19 Vaccine Shows Promise in Early-Stage Trials
Johnson & Johnson’s experimental one-shot Covid-19 vaccine generated a long-lasting immune response in an early safety study, providing a glimpse at how it will perform in the real world as the company inches closer to approaching U.S. regulators for clearance. More than 90% of participants made immune proteins, called neutralizing antibodies, within 29 days after receiving the shot, according to the report, and all participants formed the antibodies within 57 days. The immune response lasted for the full 71 days of the trial. “Looking at the antibodies, there should be good hope and good reason that the va...
Source: TIME: Health - January 14, 2021 Category: Consumer Health News Authors: Riley Griffin / Bloomberg Tags: Uncategorized COVID-19 overnight wire Source Type: news

Ad26.COV2-S Vaccine Seems Safe, Immunogenic for SARS-CoV-2
WEDNESDAY, Jan. 13, 2021 -- A candidate vaccine, Ad26.COV2.S, with a recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized severe acute respiratory syndrome coronavirus 2 spike protein is... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 13, 2021 Category: Pharmaceuticals Source Type: news

AskBio taps industry vet for C-suite role in wake of Bayer deal
Fresh off of its acquisition by Bayer AG, Research Triangle Park-based Asklepios BioPharmaceutical Inc. has created a new C-suite position and tapped an industry veteran to fill it. Dr. Katherine High has been named president of therapeutics at AskBio and will also serve on its board of directors. She will be responsible for driving the strategic direction and execution of the company’s preclinical and clinical programs. AskBio, a clinical-stage adeno-associated virus (AAV ) gene therapy company,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 13, 2021 Category: Pharmaceuticals Authors: Cameron Snipes Source Type: news

mRNA Technology Gave Us the First COVID-19 Vaccines. It Could Also Upend the Drug Industry
“No!” The doctor snapped. “Look at me!” I had been staring her in the eyes, as she had ordered, but when a doctor on my other side began jabbing me with a needle, I started to turn my head. “Don’t look at it,” the first doctor said. I obeyed. This was in early August in New Orleans, where I had signed up to be a participant in the clinical trial for the Pfizer-BioNTech COVID-19 vaccine. It was a blind study, which meant I was not supposed to know whether I had gotten the placebo or the real vaccine. I asked the doctor if I would really been able to tell by looking at the syringe. &...
Source: TIME: Health - January 11, 2021 Category: Consumer Health News Authors: Walter Isaacson Tags: Uncategorized COVID-19 feature Magazine Source Type: news

mRNA Technology Gave Us the First COVID-19 Vaccines. It Could Also Upend the Drug Industry
“No!” The doctor snapped. “Look at me!” I had been staring her in the eyes, as she had ordered, but when a doctor on my other side began jabbing me with a needle, I started to turn my head. “Don’t look at it,” the first doctor said. I obeyed. This was in early August in New Orleans, where I had signed up to be a participant in the clinical trial for the Pfizer-BioNTech COVID-19 vaccine. It was a blind study, which meant I was not supposed to know whether I had gotten the placebo or the real vaccine. I asked the doctor if I would really been able to tell by looking at the syringe. &...
Source: TIME: Science - January 11, 2021 Category: Science Authors: Walter Isaacson Tags: Uncategorized COVID-19 feature Magazine Source Type: news

Bharat Biotech to start Phase-1 trials of COVID-19 intranasal vaccine in Feb-March
Besides Covaxin, BharatBiotech has been actively working on developing another vaccine, for which it tied up with Washington UniversitySchool of Medicine in St Louis for the novel "chimp-adenovirus" (Chimpanzee adenovirus), a single dose intranasal vaccine for COVID-19. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 8, 2021 Category: Pharmaceuticals Source Type: news

South Africa to get 1.5 million COVID-19 vaccines from India
The vaccine, developed with the University of Oxford, is made from a virus which is a weakened version of a common cold virus (adenovirus), that has been genetically changed so that it is impossible for it to grow in humans. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 7, 2021 Category: Pharmaceuticals Source Type: news

More COVID-19 Vaccines Are in the Pipeline as the U.S. Effort Ramps Up
A huge U.S. study of another COVID-19 vaccine candidate got underway Monday as states continue to roll out scarce supplies of the first shots to a nation anxiously awaiting relief from the catastrophic outbreak. Public health experts say more options in addition to the two vaccines now being dispensed — one made by Pfizer and its German partner BioNTech, the other by Moderna — are critical to amassing enough shots for the country and the world. The candidate made by Novavax Inc. is the fifth to reach final-stage testing in the United States. Some 30,000 volunteers are needed to prove if the shot — a diffe...
Source: TIME: Health - December 29, 2020 Category: Consumer Health News Authors: LAURAN NEERGAARD / AP Tags: Uncategorized COVID-19 overnight wire Source Type: news

Gene therapy for placental insufficiency moves toward the clinic
(Mary Ann Liebert, Inc./Genetic Engineering News) A new study identified an adenovirus gene therapy vector carrying a VEGF isoform. It can improve uterine blood flow in placental insufficiency. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - December 15, 2020 Category: Biology Source Type: news

Study: Immunotherapy Vaccine for Mesothelioma Still Promising
The ONCOS-102 immunotherapy vaccine continues its move toward future, first-line standard of care treatment for malignant pleural mesothelioma, based upon the latest study follow-up data. When combined with standard chemotherapy, the genetically modified adenovirus has produced a median overall survival of at least 18.2 months, according to results released in late November from the ongoing clinical trial. Median overall survival was more than four months better than the control group receiving chemotherapy alone in the randomized trial. ONCOS-102 is manufactured by Targovax, a small Scandinavian biotech company focused on...
Source: Asbestos and Mesothelioma News - December 3, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Doctors warn side effects from COVID-19 vaccine "won't be a walk in the park"
(Natural News) Fevers, sweats, migraines and muscle aches that last for days – these are just some of the symptoms reported by various ‘Phase 3’ trial participants who volunteered for the vaccine trials run by Pfizer, Moderna and others. Though AstraZeneca noted in its preliminary results that its vaccine (which uses the more traditional adenovirus vector) seemed... (Source: NaturalNews.com)
Source: NaturalNews.com - November 26, 2020 Category: Consumer Health News Source Type: news

Engineered " stealth bomber " virus could be new weapon against metastatic cancer
(Emory Health Sciences) Researchers at Emory and Case Western Reserve have re-engineered an oncolytic adenovirus. The resulting virus is not easily caught by parts of the innate immune system, making systemic delivery possible without arousing a massive inflammatory reaction. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 25, 2020 Category: Cancer & Oncology Source Type: news

AstraZeneca's COVID-19 vaccine will "never be licensed in the US," says analyst
(Natural News) Because its trial designs do not meet even the basic minimum criteria set forth by the Food and Drug Administration (FDA) for new vaccines, AstraZeneca’s adenovirus-vector vaccine for the Wuhan coronavirus (COVID-19) will “never be licensed in the U.S.,” says SVB Leerink health-care analyst George Porges. Despite claims that the jab is 70... (Source: NaturalNews.com)
Source: NaturalNews.com - November 25, 2020 Category: Consumer Health News Source Type: news

Chimpanzee Adenovirus COVID - 19 Vaccine Promising in Seniors
Immunogenicity similar across age groups; vaccine better tolerated in older versus younger adults (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - November 23, 2020 Category: Respiratory Medicine Tags: Family Medicine, Geriatrics, Gynecology, Infections, Internal Medicine, Critical Care, Emergency Medicine, Nursing, Pathology, Pharmacy, Pulmonology, Journal, Source Type: news

Chimpanzee Adenovirus COVID-19 Vaccine Promising in Seniors
MONDAY, Nov. 23, 2020 -- The novel chimpanzee adenovirus-vectored vaccine, ChAdOx1 nCoV-19, is well tolerated, especially among older adults, according to a study published online Nov. 18 in The Lancet. Maheshi N. Ramasamy, D.Phil., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 23, 2020 Category: Pharmaceuticals Source Type: news

Third Covid-19 candidate vaccine developed by Janssen Pharmaceutical Companies will be tested in clinical trials involving patients in the UK
Phase 3 placebo controlled RCT will involve 30,000 patients and assess a two dose regimen of the vaccine 57 days apart, using the same human adenovirus that provided the vector for Janssen's Ebola virus vaccine. A trial of a single dose by Janssen is already underway in the US. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - November 18, 2020 Category: Consumer Health News Source Type: news

Late-Breaking 12-Month Data of Investigational RPGR Gene Therapy Shows Statistically Significant and Continued Vision Improvement in Patients with X-Linked Retinitis Pigmentosa
RARITAN, N.J., November 13, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new 12-month data from the ongoing Phase 1/2 trial (NCT03252847) of its investigational gene therapy for inherited retinal disease X-linked retinitis pigmentosa (XLRP). The data showed that low and intermediate doses were well-tolerated and continued to demonstrate statistically significant sustained or increased vision improvement across multiple metrics (mean sensitivity, volumetric and pointwise) and modalities (full-field static perimetry and microperimetry). Data on the novel adeno-associated virus re...
Source: Johnson and Johnson - November 13, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Researchers use bovine adenovirus to develop novel COVID-19 vaccine
(Penn State) A researcher in Penn State's College of Agricultural Sciences is part of a team of scientists working to develop a unique COVID-19 vaccine that uses a bovine adenovirus as a safe and effective delivery vehicle. With support from a nearly $3.9 million grant from the National Institutes of Health, the team aims to create a vaccine that will protect all segments of the population, especially older adults. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - October 7, 2020 Category: Infectious Diseases Source Type: news

Johnson & Johnson ’ s Coronavirus Vaccine Enters Phase 3 Trial With Beth Israel
cbsoptanon.onScriptsReady(function(cmp){cmp.ot.targetingAllowed(function(a){if(a) AnvatoPlayer("p1").init({"mcp":"cbs","width":"100%","height":"100%","video":"4730668","autoplay":false,"titleVisible":false,"accessKey":"EZqvRyKE7qmqDflDPXIw6U7kKZEA0Vx7","accessControl":{"preview":false},"pInstance":"p1","plugins":{"heartbeat":{"account":"cbslocal-global-unified","publisherId":"cbslocal","jobId...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - September 23, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Covid-19 Boston, MA Health Healthcare Status Beth Israel Deacones Medical Center Coronavirus Johnson & Johnson Source Type: news

Gene Therapy Clinical Trial for Mesothelioma Moving Forward
This study will compare the effectiveness of the drug against a control group receiving only the gemcitabine and celecoxib. Patients have a one-in-two chance of being randomly assigned to either the adenovirus treatment or the control group. Adenovirus-delivered interferon Alpha-2b is designed as a second- or third-line treatment for patients who have failed in earlier regimens. Patients who previously had aggressive mesothelioma surgery but whose tumors have since progressed would be eligible to enroll. Success at the phase III level would mark the culmination of 20 years of researching and fine tuning gene therapy for us...
Source: Asbestos and Mesothelioma News - September 23, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

The Great Vaccine Race: Inside the Unprecedented Scramble to Immunize the World Against COVID-19
The cleverest of enemies thrive on surprise attacks. Viruses—and coronaviruses in particular—know this well. Remaining hidden in animal hosts for decades, they mutate steadily, sometimes serendipitously morphing into more effective and efficient infectious agents. When a strain with just the right combination of genetic codes that spell trouble for people makes the leap from animal to human, the ambush begins. Such was the case with SARS-CoV-2, the coronavirus behind COVID-19, and the attack was mostly silent and insidious at first. Many people infected with SARS-CoV-2 remained oblivious as they served as the v...
Source: TIME: Health - September 10, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Magazine Source Type: news

Vector-Based Vaccines Come to the Fore in the COVID-19 Pandemic
Adenovirus vectors deliver the genetic instructions for SARS-CoV-2 antigens directly into patients' cells, provoking a robust immune response. But will pre-existing immunity from common colds take... (Source: The Scientist)
Source: The Scientist - September 8, 2020 Category: Science Tags: News & Opinion Source Type: news

Johnson & Johnson announces that Janssen's COVID-19 investigational vaccine candidate prevents severe clinical disease in pre-clinical studies
Janssen's lead SARS-CoV-2 investigational vaccine candidate, Ad26.COV2.S, prevented severe clinical disease in Syrian golden hamsters, upon challenge with SARS-CoV-2, the virus that causes COVID-19 in people. The data, published in Nature Medicine, demonstrated that the Company's investigational adenovirus serotype 26 (Ad26) vector-based vaccineJanssen's lead SARS-CoV-2 investigational vaccine candidate, Ad26.COV2.S, prevented severe (Source: World Pharma News)
Source: World Pharma News - September 7, 2020 Category: Pharmaceuticals Tags: Featured Johnson & Business and Industry Source Type: news

Johnson & Johnson Announces that Janssen ’s COVID-19 Investigational Vaccine Candidate Prevents Severe Clinical Disease in Pre-clinical Studies
Janssen’s lead SARS-CoV-2 investigational vaccine candidate, Ad26.COV2.S, prevented severe clinical disease in Syrian golden hamsters, upon challenge with SARS-CoV-2, the virus that causes COVID-19 in people. The data, published today in Nature Medicine, demonstrated that the Company’s investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited an immune response as demonstrated by “neutralizing antibodies” and prevented severe clinical disease – including weight loss, pneumonia and mortality – in Syrian golden hamsters upon challenge.This publication follows Johnson &...
Source: Johnson and Johnson - September 3, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Toxicity of dorsal root ganglia is widely associated with CNS AAV gene therapy
(Mary Ann Liebert, Inc./Genetic Engineering News) A meta-analysis of non-human primate (NHP) studies showed that adeno-associated virus (AAV) gene therapy often caused dorsal root ganglion (DRG) pathology. There were no clinical effects. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 2, 2020 Category: International Medicine & Public Health Source Type: news

Approval of a Coronavirus Vaccine Would Be Just the Beginning – Huge Production Challenges Could Cause Long Delays
This article is republished from The Conversation under a Creative Commons license. Read the original article. The post Approval of a Coronavirus Vaccine Would Be Just the Beginning – Huge Production Challenges Could Cause Long Delays appeared first on Inter Press Service. (Source: IPS Inter Press Service - Health)
Source: IPS Inter Press Service - Health - August 25, 2020 Category: International Medicine & Public Health Authors: External Source Tags: Global Headlines Health TerraViva United Nations Source Type: news

Small change makes cancer vaccine more effective in animal tests
(Thomas Jefferson University) Tweaking the adenovirus spike protein induces a more robust immune reaction for a cancer vaccine against gastric, pancreatic, esophageal and colon malignancies in animal models. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 24, 2020 Category: International Medicine & Public Health Source Type: news

StrideBio Expands Leadership Team with Appointment of William Monteith as Chief Operating Officer
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2020 -- (Healthcare Sales & Marketing Network) -- StrideBio, Inc, a leading developer of novel engineered adeno-associated virus (AAV) based gene therapies, today announced the appointment of William (Bill) Monteith ... Biopharmaceuticals, Personnel StrideBio , gene therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 11, 2020 Category: Pharmaceuticals Source Type: news

CDC Warns Parents To Be On Lookout For Acute Flaccid Myelitis In Children
(CNN) — Parents and pediatricians need to be on the lookout in the coming months for a rare, paralyzing condition that affects young children, the Centers for Disease Control and Prevention said Tuesday. The polio-like condition, called acute flaccid myelitis or AFM, tends to peak every other year, and the last surge of cases was in 2018, when 238 cases were diagnosed across the US, the CDC said. Read: Acute Flaccid Myelitis Fact Sheet This year is likely to see another upsurge but things will be complicated by the coronavirus pandemic. “AFM is a priority for CDC as we prepare for a possible outbreak this ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - August 5, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Featured Health Syndicated CBSN Boston Acute Flaccid Myelitis CNN Source Type: news

Single Dose of Johnson & Johnson COVID-19 Vaccine Candidate Demonstrates Robust Protection in Pre-clinical Studies
NEW BRUNSWICK, N.J., July 30, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that its lead vaccine candidate protected against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies. The data, published in Nature, show the Company’s investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited a robust immune response as demonstrated by “neutralizing antibodies,” successfully preventing subsequent infection and providing complete or near-complete protection in the lungs from the virus in non-human primates (NHPs) in the pre-clinical s...
Source: Johnson and Johnson - July 30, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Single dose of Johnson & Johnson COVID-19 vaccine candidate demonstrates robust protection in pre-clinical studies
Johnson & Johnson (NYSE: JNJ) (the Company) today announced that its lead vaccine candidate protected against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies. The data, published in Nature, show the Company's investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited a robust immune response as demonstrated by "neutralizing antibodies," successfully preventing subsequent infection and providing complete or near-complete protection in the lungs from the virus in non-human primates (NHPs) in the pre-clinical study. (Source: World Pharma News)
Source: World Pharma News - July 30, 2020 Category: Pharmaceuticals Tags: Featured Johnson & Business and Industry Source Type: news

Chimpanzee Adenovirus-Vectored Vaccine Promising for COVID-19
FRIDAY, July 24, 2020 -- A chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19) expressing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein has acceptable safety and induces antibody and T-cell immune responses,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 24, 2020 Category: Pharmaceuticals Source Type: news

Ad5-Vectored COVID-19 Vaccine Immunogenic in Healthy Adults
THURSDAY, July 23, 2020 -- The nonreplicating adenovirus type-5 (Ad5)-vectored COVID-19 vaccine appears safe and induces immune responses at a dose of 5 ×1010 viral particles, according to a study published online July 20 in The Lancet. Feng-Cai... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 23, 2020 Category: Pharmaceuticals Source Type: news

Merck, Targovax Team Up for New Mesothelioma Clinical Trial
Standard-of-care treatment for malignant mesothelioma could change significantly, depending upon the results of an upcoming clinical trial of two immunotherapy agents used in combination with chemotherapy. The mesothelioma clinical trial will involve pembrolizumab, also known by the brand name Keytruda, and its synergy with ONCOS-102, a lesser-known, genetically modified adenovirus. Individually, both have shown modest efficacy for mesothelioma patients when used with chemotherapy. Together, there is potential for a much greater impact in significantly extending patient survival. The clinical trial is a partnership between...
Source: Asbestos and Mesothelioma News - July 22, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news